



July 1, 2025

To whom it may concern

Company name: TAKASAGO INTERNATIONAL CORPORATION
Name of representative: Satoshi Masumura
President and Chief Executive Officer
(Securities code: 4914; TSE Prime Market)
Inquiries: Shigeki Kawabata
Director; Senior Vice President
General Manager, Corporate Strategy & Planning Division
(Telephone: +81-03-5744-0523)

Notice Concerning Acquisition of Land in Kamakura City, Kanagawa Prefecture in Japan

TAKASAGO INTERNATIONAL CORPORATION (the “Company”) hereby announces that the Company acquired the Land on June 30, 2025 pursuant to the contract for sale of real estate with Chugai Pharmaceutical Co., Ltd. (Head office: Chuo-ku, Tokyo) .

1. Reason for Acquisition

Takasago group has developed its business based on technology cultivated through R&D since founding, in line with the corporate mission “Create new value through innovation rooted in *kaori*”. In addition, the Company pursues to expand its global business with the Vision 2040 and the slogan “Care for People, Respect the Environment”, to achieve sustainable growth and enhancement of corporate value. In line with the Vision 2040, the Company acquired the land to construct a new R&D center as “Center of Excellence” for Takasago group to enhance its R&D system with a mid-to long-term perspective.

2. Details of Acquired Assets

| | | |
|-------|-----------|---|
| (1) | Usage | Site for construction of the Company’s R&D center |
| (2) | Address | Kajiwara area, Kamakura City, Kanagawa Prefecture |
| (3) | Land area | 32,524.62 m ² (registered area) |

3. Seller Summary

The Company and Chugai Pharmaceutical Co., Ltd. have no notable capital relationship, personal relationship or business relationship.

4. Transaction Price

The transaction price is within the range of the Tokyo Stock Exchange’s timely disclosure guidelines for the acquisition of fixed assets.

5. Outlook for the Future

The impact on this matter is expected to be minor.